AstraZeneca Long Acting Antibody Granted FDA EUA for COVID-19 Prevention
AstraZeneca (AZN) product Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with the first doses expected to become available very soon.
The EUA for Evusheld was granted for . . .
This content is for paid subscribers.
Today’s Highlights
December 9, 2021
